Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Get Free Report) Director Kevin Charles Gorman sold 146,105 shares of the company’s stock in a transaction on Monday, January 27th. The stock was sold at an average price of $149.46, for a total transaction of $21,836,853.30. Following the sale, the director now directly owns 514,596 shares of the company’s stock, valued at approximately $76,911,518.16. This represents a 22.11 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link.
Neurocrine Biosciences Trading Down 0.0 %
Shares of NBIX opened at $150.68 on Thursday. The stock has a 50 day simple moving average of $135.33 and a 200-day simple moving average of $131.30. The stock has a market cap of $15.26 billion, a PE ratio of 40.40 and a beta of 0.33. Neurocrine Biosciences, Inc. has a 1 year low of $110.95 and a 1 year high of $157.98.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently made changes to their positions in NBIX. Golden State Wealth Management LLC bought a new stake in shares of Neurocrine Biosciences in the 4th quarter worth about $25,000. Brooklyn Investment Group increased its holdings in shares of Neurocrine Biosciences by 99.1% during the fourth quarter. Brooklyn Investment Group now owns 231 shares of the company’s stock worth $32,000 after buying an additional 115 shares in the last quarter. Blue Trust Inc. raised its stake in shares of Neurocrine Biosciences by 171.9% in the third quarter. Blue Trust Inc. now owns 348 shares of the company’s stock valued at $40,000 after acquiring an additional 220 shares during the last quarter. R Squared Ltd acquired a new position in shares of Neurocrine Biosciences in the 4th quarter worth approximately $61,000. Finally, UMB Bank n.a. grew its position in Neurocrine Biosciences by 211.6% during the 4th quarter. UMB Bank n.a. now owns 455 shares of the company’s stock worth $62,000 after acquiring an additional 309 shares during the last quarter. 92.59% of the stock is owned by institutional investors.
Analyst Upgrades and Downgrades
Check Out Our Latest Stock Analysis on NBIX
About Neurocrine Biosciences
Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.
Further Reading
- Five stocks we like better than Neurocrine Biosciences
- What is the Euro STOXX 50 Index?
- Coinbase Gains Momentum on App Store—What It Means for the Stock
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- How to Short Sell Stocks Like a Pro: Strategies and Tips
- P/E Ratio Calculation: How to Assess Stocks
- 3 Steel Stocks Soaring After Tariff Announcements
Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.